Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00054470
Recruitment Status : Withdrawn
First Posted : February 6, 2003
Last Update Posted : June 29, 2012
National Cancer Institute (NCI)
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio

February 5, 2003
February 6, 2003
June 29, 2012
December 2002
January 2003   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00054470 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
A Phase II Evaluation Of The Efficacy And Safety Of R115777 (NSC702818) A Non-Peptidomimetic Farnesyl Transferase Inhibitor, And Trastuzumab In Patients With Advanced Breast Cancer

RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining tipifarnib with trastuzumab may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining tipifarnib with trastuzumab in treating patients who have metastatic breast cancer.


  • Determine the antitumor activity of tipifarnib and trastuzumab (Herceptin) in patients with metastatic breast cancer.
  • Determine the safety and tolerability of this regimen in these patients.

OUTLINE: This is an open-label, multicenter study.

Patients receive oral tipifarnib twice daily on days 1-21 and trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed every 2 months.

PROJECTED ACCRUAL: A total of 18-40 patients will be accrued for this study within 9-20 months.

Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Cancer
  • Biological: trastuzumab
  • Drug: tipifarnib
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
January 2003
January 2003   (Final data collection date for primary outcome measure)


  • Histologically or cytologically confirmed metastatic adenocarcinoma of the breast

    • HER2/neu 3+ by immunohistochemical staining

      • 2+ eligible provided HER2/neu positive by fluorescent in-situ hybridization (FISH)
      • HER2/neu positive by FISH alone allowed
  • Unidimensionally measurable disease

    • At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  • Must have received prior trastuzumab (Herceptin)
  • Patients with known brain metastases meeting any of the following criteria are not eligible:

    • Require high-dose steroid therapy or enzyme-inducing anticonvulsant drugs
    • No prior cranial radiotherapy
    • Have progressive neurologic dysfunction that would preclude study evaluation
    • Have evidence of progressive CNS disease by CT scan or MRI
  • Hormone receptor status:

    • Not specified



  • Over 18


  • Male or female

Menopausal status

  • Not specified

Performance status

  • ECOG 0-2 OR
  • Karnofsky 70-100%

Life expectancy

  • At least 12 weeks


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 9.0 g/dL


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present)


  • Creatinine no greater than 1.5 times ULN OR
  • Creatinine clearance greater than 60 mL/min


  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • Ejection fraction greater than 50% by MUGA or echocardiogram


  • No gastrointestinal tract disease resulting in an inability to tolerate oral medication
  • No requirement for IV alimentation
  • No active peptic ulcer disease


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No significant traumatic injury within the past 21 days
  • No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
  • No ongoing or active infection
  • No prior allergic reaction attributed to compounds of similar chemical or biological composition to tipifarnib (e.g., quinolones) or trastuzumab
  • No psychiatric illness or social situation that would preclude study compliance
  • No other concurrent medical illness that would preclude study compliance


Biologic therapy

  • See Disease Characteristics
  • No prior bone marrow transplantation with high-dose chemotherapy
  • No concurrent immunotherapy


  • See Biologic therapy
  • No more than 2 prior chemotherapy regimens for metastatic disease
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

    • Prior combination chemotherapy allowed
  • No concurrent chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • Prior hormonal therapy allowed
  • No concurrent hormonal therapy for cancer


  • See Disease Characteristics
  • More than 4 weeks since prior wide-field radiotherapy and recovered
  • No concurrent radiotherapy


  • Prior modified radical mastectomy or lumpectomy with axillary node dissection allowed
  • Prior resection of metastatic lesions allowed
  • More than 21 days since prior major surgery
  • No prior surgery affecting absorption


  • No prior tipifarnib
  • More than 6 weeks since initiation of bisphosphonate therapy (if bone lesions are the only site of measurable disease)
  • Bisphosphonate therapy may not be initiated during study
  • No other concurrent investigational agents
  • No other concurrent anticancer therapy
  • No concurrent antacids within 2 hours of study drug
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
U01CA069853 ( U.S. NIH Grant/Contract )
P30CA054174 ( U.S. NIH Grant/Contract )
SACI-IDD-01-44 ( Other Identifier: San Antonio Cancer Institute )
NCI-5330 ( Other Identifier: NCI )
UTHSC-IDD-01-44 ( Other Identifier: UTHSCSA IRB )
Not Provided
Not Provided
The University of Texas Health Science Center at San Antonio
The University of Texas Health Science Center at San Antonio
National Cancer Institute (NCI)
Study Chair: Garry Schwartz, MD Brooke Army Medical Center
The University of Texas Health Science Center at San Antonio
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP